Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

NCT06057402 · tracked via the Priya Life Science USA tracker

Sponsor

Pfizer

Phase

Phase 4

Started

2023-10-03

Last updated

2026-07-01

Condition(s) studied

Multiple Myeloma

Investigational drug(s) / intervention(s)

Elranatamab

Elranatamab: Elranatamab is a heterodimeric humanized full-length bispecific IgG2 kappa antibody that targets BCMA on MM cells and CD3 on T cells

Study summary

This is a post-trial access (PTA) open-label, single-arm study in Multiple Myeloma participants who continue to derive clinical benefit from elranatamab monotherapy in the Pfizer-sponsored elranatamab Parent Studies.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Participants must agree to follow the reproductive criteria as outlined in the protocol * Participants have completed a qualifying Parent Study, were still receiving elranatamab when the Parent Study terminated or completed, and are deriving clinical benefit from elranatamab (as determined by the investigator). Exclusion Criteria: * Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study. * Participants not previously enrolled or who have discontinued study treatment in a Parent Study are ineligible for participation in this study.

Primary outcome measure(s)

Incidence of nonserious adverse events (AEs) leading to permanent discontinuation — A minimum of 90 days after the last dose of study drug
Incidence of serious adverse events (SAEs) — A minimum of 90 days after the last dose of study drug

Trial sites (33)

Facility	City	Region	Status
UCI Health - Irvine Infusion Pharmacy ACC	Irvine	California	Recruiting
UC Irvine Health	Orange	California	Recruiting
UCI Health	Orange	California	Recruiting
UCHealth Poudre Valley Hospital	Fort Collins	Colorado	Recruiting
UCHealth Harmony	Fort Collins	Colorado	Recruiting
UCHealth Greeley Hospital	Greeley	Colorado	Recruiting
Longs Peak Hospital	Longmont	Colorado	Recruiting
UCHealth Longs Peak Medical Center	Longmont	Colorado	Recruiting
UCHealth - Medical Center of the Rockies	Loveland	Colorado	Recruiting
Sylvester Comprehensive Cancer Center - The Lennar Foundation Medical Center	Coral Gables	Florida	Recruiting
University of Miami Hospital and Clinics Deerfield Beach	Deerfield Beach	Florida	Recruiting
Sylvester Comprehensive Cancer Center	Miami	Florida	Recruiting
University of Miami Hospital and Clinics - Griffin Cancer Research Building	Miami	Florida	Recruiting
University of Miami Hospital and Clinics	Miami	Florida	Recruiting
University of Michigan	Ann Arbor	Michigan	Recruiting
Henry Ford Cancer - Detroit (Brigitte Harris Cancer Pavilion)	Detroit	Michigan	Recruiting
St. David's South Austin Medical Center	Austin	Texas	Recruiting
Epworth Freemasons	Melbourne	Victoria	Recruiting
Epworth Hospital	Richmond	Victoria	Recruiting
Slade Pharmacy	Richmond	Victoria	Recruiting
Arthur J.E. Child Comprehensive Cancer Centre	Calgary	Alberta	Recruiting
Cross Cancer Institute	Edmonton	Alberta	Recruiting
McGill University Health Centre	Montreal	Quebec	Recruiting
Peking University Third Hospital	Beijing	Beijing Municipality	Active Not Recruiting
Sun Yat-sen University Cancer Center	Guangzhou	Guangdong	Active Not Recruiting
Shandong Provincial Hospital	Jinan	Shandong	Recruiting
The first Affiliated Hospital, Zhejiang University School of Medicine	Hangzhou	Zhejiang	Recruiting
Japanese Red Cross Medical Center	Shibuya-ku	Tokyo	Recruiting
University Hospital,Kyoto Prefectural University of Medicine	Kyoto	Japan	Recruiting
Clinica Universidad de Navarra	Pamplona	Navarre	Recruiting
Hospital Universitario Doctor Peset	Valencia	València	Recruiting
National Taiwan University Hospital	Taipei	Taiwan	Recruiting
Taipei Veterans General Hospital	Taipei	Taiwan	Recruiting

More Pfizer trials in the USA

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania Active, not recruiting

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine Recruiting

A Real-life Study to Understand the Use and Effects of Palbociclib in US Patients With Breast Cancer Active, not recruiting

Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer Active, not recruiting

A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants Recruiting

Other trials for the same condition

A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma Active, not recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat in Participants With RRMM Active, not recruiting

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma Recruiting

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM Active, not recruiting

Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06057402 on ClinicalTrials.gov ↗ ← All trials in the USA